References: 1. Horizant [package insert] Woburn, MA: Azurity Pharmaceuticals, Inc.; 2022. 2. Cundy KC, Sastry S, Luo W, et al. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol. 2008;48(12):1378-1388. 3. Lee DO, Ziman RB, Perkins AT, et al; XP053 Study Group. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7(3):282-292. 4. Zhang L, Rainka M, Freeman R, et al. A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748). J Pain. 2013;14(6):590-603. 5. Silber MH, Buchfuhrer MJ, Earley CJ, et al. The management of restless legs syndrome: an updated algorithm. Mayo Clin Proc. 2021;96(7):1921-1937. 6. Gralise [prescribing information]. Morristown, NJ: Almatica Pharma LLC. 7. Neurontin [prescribing information]. New York, NY: Parke-Davis Division of Pfizer Inc. 8. Restless Legs Syndrome. Mayo Clinic. Accessed January 20, 2023. https://www.mayoclinic.org/diseases-conditions/restless-legs-syndrome/symptoms-causes/syc-20377168 9. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005;165(11):1286-1292. 10. Restless Legs Syndrome Fact Sheet. National Institute of Neurological Disorders and Stroke. Accessed January 20, 2023. https://www.ninds.nih.gov/restless-legs-syndrome-fact-sheet 11. Restless Legs Syndrome (RLS). HelpGuide.org. Accessed January 20, 2023. https://www.helpguide.org/articles/sleep/restless-leg-syndrome-rls.htm 12. Postherpetic Neuralgia. Mayo Clinic. Accessed January 20, 2023. https://www.mayoclinic.org/diseases-conditions/postherpetic-neuralgia/symptoms-causes/syc-20376588 13. Sacks GM. Unmet need in the treatment of postherpetic neuralgia. Am J Manag Care. 2013;19(1 suppl):S207-S213. 14. Calkins AM, Gudin J, Gidal B, et al. Impact of data imputation methodology on pain assessment over 24 hours in a randomized, placebo-controlled study of gabapentin enacarbil in patients with neuropathic pain associated with postherpetic neuralgia. Pain Medicine. 2016;17(4):728-736. 15. Swearingen D, Aronoff GM, Ciric S, et al. Pharmacokinetics of immediate release, extended release, and gastric retentive gabapentin formulations in healthy adults. Int J Clin Pharmacol Ther. 2018;56(5):231-238. 16. Kanodia SK, Seth A, Dixit AM. Dose related efficacy of gabapentin in acute herpetic neuralgia among geriatric patients. Indian J Dermatol. 2012;57(5):362-365.